Kestra Medical Technologies (NASDAQ:KMTS) Releases Earnings Results

Posted by Brian Himes on Jul 14th, 2026

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.67) earnings per share for the quarter, FiscalAI reports. Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The business had revenue of $28.64 million for the quarter.

Kestra Medical Technologies Trading Down 2.3%

Shares of KMTS stock traded down $0.58 during trading hours on Tuesday, reaching $24.18. 425,932 shares of the stock traded hands, compared to its average volume of 339,913. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.41 billion, a PE ratio of -6.11 and a beta of 0.47. Kestra Medical Technologies has a 1-year low of $13.25 and a 1-year high of $30.00. The business has a fifty day moving average price of $22.01 and a 200 day moving average price of $22.77.

Analyst Upgrades and Downgrades

KMTS has been the topic of a number of research reports. Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. BTIG Research reaffirmed a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, The Goldman Sachs Group lowered their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $27.40.

Read Our Latest Report on Kestra Medical Technologies

Insider Buying and Selling at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00. Following the transaction, the insider owned 395,467 shares of the company’s stock, valued at $8,229,668.27. The trade was a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 45,000 shares of company stock worth $927,150 in the last quarter. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors and hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC acquired a new position in shares of Kestra Medical Technologies during the 4th quarter valued at about $31,000. Russell Investments Group Ltd. grew its position in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. Daiwa Securities Group Inc. bought a new position in shares of Kestra Medical Technologies in the fourth quarter worth about $72,000. BNP Paribas Financial Markets lifted its position in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the last quarter. Finally, Brown Brothers Harriman & Co. boosted its stake in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after purchasing an additional 656 shares during the period.

Kestra Medical Technologies Company Profile

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.